Business Wire

Airgain Signs Strategic Memorandum of Understanding With COMPAL, a Global Fortune 500 Leader, on Airgain’s 5G Smart FWA Technology

30.5.2024 15:55:00 EEST | Business Wire | Press release

Share

Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, has signed a strategic Memorandum of Understanding (MOU) with Compal Electronics, Inc. (TAIEX: 2324), a global fortune 500 leader in smart device manufacturing, on a comprehensive plan for commercialization of a 5G Smart Fixed Wireless Access (FWA) technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530558164/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yiyun Chang, Vice President at Compal Electronics, Inc. (left), shaking hands with Dr. Ali Sadri, CTO of Airgain, Inc., after signing a strategic MOU. (Photo: Business Wire)

The agreement signals a major step towards enabling mass production of this transformative technology which has the potential to substantially enhance 5G customer experience and mobile network operator (MNO) capabilities.

Airgain Smart LanternTM uses patent-pending smart beamforming technology to simplify end-user FWA deployment as well as reducing truck roll and professional installation, by automatically determining the direction of the best received and transmitted signal from the 5G cellular base station (gNb).

Preliminary testing results indicate a performance enhancement exceeding 25% in both throughput and range when compared to conventional indoor and outdoor omnidirectional Fixed Wireless Access (FWA) Customer Premises Equipment (CPE).

The MOU commits the two companies to a collaboration which will see them evaluate the technology’s 5G KPI enhancements and assess the feasibility, effectiveness, and opportunities for original equipment manufacturer (OEM) and original device manufacturer (ODM) for FWA device development.

At the heart of the innovation is Airgain’s first-of-its-kind smart antenna technology for 5G mid-band and C-band frequencies, and novel beamforming algorithms. When combined with COMPAL’s expertise in developing FWA modules leveraging leading 5G chipset providers, this will deliver a powerful value proposition to their customers.

According to the forecast presented in the Ericsson Mobility Report, the Fixed Wireless Access (FWA) market is projected to reach a valuation of $67 billion by the year 2028, which equates to a Compound Annual Growth Rate (CAGR) of 16% year-over-year. Smart Lantern's FWA technology holds the potential to significantly drive the adoption of FWA technology among Mobile Network Operators (MNOs).

Dr. Ali Sadri, CTO of Airgain, Inc., heralded the MOU as a significant moment in bringing Smart LanternTM to market, adding:

“As we embark on this ground-breaking journey towards enabling commercialization, the signing of this MOU with COMPAL signifies a strategic leap forward in realizing the full potential of our innovative product, Smart LanternTM.

“Having demonstrated its feasibility and generated tremendous excitement at Mobile World Congress, this MOU underscores our commitment to translating that enthusiasm into tangible market success. This momentous partnership solidifies Airgain's position as a trailblazer in delivering cutting-edge solutions that shape the future landscape of wireless communication.”

Yiyun Chang, Vice President at Compal Electronics, Inc., said:

“COMPAL’s mission is to foster collaborative innovation and make ideas happen. Our collaboration with Airgain is built on shared dedication to pushing the boundaries of what's possible in the telecommunications industry. We are confident that this partnership will not only meet but exceed the expectations of telecom equipment manufacturers (TEMs), MNOs, and system integrators (SI).

“Together, we are poised to redefine the standards and capabilities of wireless communication, reinforcing COMPAL’s commitment to delivering state-of-the-art solutions that shape the future of connectivity.”

For more information about Smart LanternTM visit airgain.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Airgain Media Contact
Martyn Gettings +44 7831 158416
pr@airgain.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye